ArticleJournal of medical case reports2025
Rituximab-induced serum sickness in progressive transformation of germinal centers immunoglobulin G4-related disease: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSerum sickness, a type III hypersensitivity reaction, can arise from various triggers such as vaccines, anti-venoms, and certain medications, particularly monoclonal antibodies. Rituximab, a monoclonal antibody targeting CD20 on B-cells, is known to induce a subtype of this reaction called rituximab-induced serum sickness, which primarily affects those with rheumatologic diseases. CASE PRESENTATION: A 34-year-old Mexican-American female patient with focal segmental glomerulosclerosis was treated with rituximab for concomitant immunoglobulin G4-related disease. After her third infusion, she developed a rash, myalgias, arthralgias, and proteinuria, leading to a diagnosis of rituximab-induced serum sickness, which resolved with a prednisone taper.
conclusionSerum sickness should be considered as a potential differential diagnosis in patients exhibiting nonspecific systemic symptoms and dermatologic manifestations following exposure to a triggering factor, such as a newly administered monoclonal antibody medication. This is the first known case of rituximab-induced serum sickness in the context of immunoglobulin G4-related disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.